

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Prospect Waterbury, Inc. d/b/a The Waterbury Hospital</p> <p>2. 64 Robbins Street Waterbury, CT 06721</p>	<p>In accordance with letters dated September 30 and October 5, 2016</p> <p>3. License number: 06-02406-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: March 31, 2026</p> <p>5. Docket No.: 030-01251 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Isotope Products Laboratories, Model NES-8412; North American Scientific, Inc., Model MED 3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 2.5 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p> <p>D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).</p>

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

06-02406-01

Docket or Reference Number

030-01251

Amendment No. 73

**CONDITIONS**

10. Licensed material may be used or stored at the licensee's facilities located at:
1. 64 Robbins Street, Waterbury, Connecticut
  2. 455 Chase Parkway, Waterbury, Connecticut
11. The Radiation Safety Officer (RSO) for this license is Thomas J. LaRocca, M.S., DABR.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
  - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Duncan Belcher, M.D.

35.100, 35.200, 35.300

Anthony R. Carter, M.D.

35.100, 35.200, 35.500, Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries

Kenneth S. Allen, M.D.

35.100, 35.200, 35.500

Jeffrey A. Bitterman, M.D.

35.300

Erick A. Hyson, M.D.

35.100, 35.200, 35.500, Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries

Andrew Lawson, M.D.

35.100, 35.200, Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries, Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

Marco Verga, M.D.

35.100, 35.200

Joseph Ravalese, III, M.D.

35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
06-02406-01Docket or Reference Number  
030-01251

Amendment No. 73

Authorized User(M.D.,D.O.,etc.)

Kevin G. Kett, M.D.

Mark L. Ruggiero, M.D.

Douglas Housman, M.D.

Ehsan Ansari, M.D.

Material and Use


35.100, 35.200

35.200

Oral administration of sodium iodide I-131

35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
06-02406-01Docket or Reference Number  
030-01251

Amendment No. 73

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 23, 2015 [ML15338A022]
  - B. Letter dated February 4, 2016 [ML16076A127]
  - C. Letter dated March 3, 2016 [ML16076A175]
  - D. Letter dated June 30, 2016 [ML16193A035]
  - E. Letter dated September 29, 2016 [ML16274A110]
  - F. Letter dated October 5, 2016 [ML16286A581]
  - G. Letter dated November 10, 2016 [ML16337A011]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 13, 2016By: Janice NguyenJanice Nguyen  
Region I